LIGAND PHARMACEUTICALS INCORPORATED

LGNYZ ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-1.9M
Depreciation & Amortization $4.6M
Depreciation
Amortization
Stock-Based Compensation $3.4M
Net Cash from Operating Activities $-33.8M
Investing Activities
Capital Expenditures $522.0K
Business Acquisitions
Net Cash from Investing Activities $24.8M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $-3.7M
Net Change in Cash $-12.7M
Free Cash Flow $-34.3M
← Newer Page 3 of 3 Older →